VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31

VivoSim Labs, INC.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.16+0.00 (+0.38%)

Close on Oct 19, 2026

Market cap: $825.22K
P/E (TTM): –
Dividend yield: –

VivoSim Labs, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31	FY 2018 2018-03-31	FY 2017 2017-03-31	FY 2016 2016-03-31	FY 2015 2015-03-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	0.13	0.14	0.11	0.37	1.50	0	2.20	3.09	4.60	4.23	1.48	0.57	1.20	0.97	0.60	–	–
Cost of Revenue	0	0.01	–	–	–	0	0.30	0.50	1.00	0.96	0	0	–	0.12	–	–	–
Gross Profit	0.13	0.14	–	–	–	0	1.90	2.59	3.60	3.27	1.48	0.57	–	0.85	–	–	–
Research & Development	4.19	5.03	5.50	8.89	3.32	1.10	5.28	15	18	20	18	13	3.44	1.42	1.20	–	–
Selling, General & Admin	7.43	7.73	9.70	9.22	9.66	16	18	15	21	22	22	18	7.08	1.73	0.58	–	–
Total Costs & Expenses	12	13	15	18	13	17	24	30	40	43	40	31	–	–	–	–	–
Operating Income	-11	-13	-15	-18	-11	-17	-21	-27	-35	-39	-39	-30	-9.32	-2.31	-1.18	–	–
Interest Expense	0.01	0.01	–	–	–	–	–	–	–	0	0	0.00	1.09	2.07	0.16	–	–
Interest & Investment Income	0.27	0.14	0.41	0.45	0.01	0.02	0.59	0.71	0.48	0.20	0.09	0.03	0.01	–	–	–	–
Other Non-Operating Income	-2.35	10	0.42	0.47	0.03	0.00	2.77	0.64	0.47	0.15	0.07	0.22	-34	-2.08	-0.16	–	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	2.10	2.10	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–
Gain (Loss) on Investments	0.09	0	0.01	0.03	0	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0	10	0	-0.01	0	-0.02	0.11	-0.06	0.00	-0.05	0	-0.01	-0.16	–	–	–	–
Pretax Income	-14	-2.49	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-14	-2.49	-15	-17	-11	-17	-19	-27	-35	-38	-39	-30	-44	-4.38	-1.34	-0.87	-0.10
Net Income	-14	-2.49	-15	-17	-11	-17	-19	-27	-35	-38	-39	-30	-44	–	–	–	–
EPS (Basic)(per share)	-5.35	-1.70	-19.25	-23.76	-15.84	-29.28	-33.60	-55.20	-76.80	-93.60	-103.20	-91.20	-242.40	-45.60	-21.60	–	–
EPS (Diluted)(per share)	-5.35	-1.70	-19.25	-23.76	-15.84	-29.28	-33.60	-55.20	-76.80	-93.60	-103.20	-91.20	-242.40	-45.60	0.00	–	–
Shares Outstanding (Basic, Weighted)(shares)	2.59	1.46	0.76	0.73	0.73	0.58	0.54	0.48	0.45	0.41	0.38	0.33	0.18	0.10	0.06	–	–
Shares Outstanding (Diluted, Weighted)(shares)	2.59	1.46	0.76	0.73	0.73	0.58	0.54	0.48	0.45	0.41	0.38	0.33	0.18	0.10	0.06	–	–
EBITDA	-11	-12	-15	-17	-11	-17	-20	-26	-34	-37	-38	-30	-9.12	-2.24	-1.12	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 117.0%
Operating margin: -10117.0%
Net margin: -11016.1%
Return on equity, FY2026: -294.8%

Financial strength

Current ratio: 1.70
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 88.2%

Valuation

P/E ratio: –
Price to sales: 7.37
Price to book: –
Dividend yield: –